First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study
First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study
Inivata’s InVisionFirst®-Lung is being used for ctDNA testing and monitoring of patients treated with lorlatinib
Study
supported by a grant from Pfizer Inc.
Research Triangle Park, NC, USA and Cambridge, UK, 20 January 2021 – Inivata, a leader in liquid biopsy, today announces that the first patients have been tested using InVisionFirst®-Lung as part of the Phase II ALKALINE trial sponsored by the European Organisation for Research and Treatment of Cancer (EORTC). As part of the study Inivata’s InVisionFirst-Lung liquid biopsy will be used to test and monitor ALK positive non-small cell lung cancer (NSCLC) patients initiating treatment with lorlatinib, Pfizer Inc.’s third generation ALK inhibitor therapy.